Shilpa Medicare Limited has announced that it will hold its Q4FY26 earnings conference call on Friday, May 22, 2026, at 16:00 hrs. The call is being conducted pursuant to Regulation 30(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The management will discuss the financial results for the fourth quarter and the year ended March 31, 2026.

Earnings Conference Call Details

The company has provided the following schedule and access details for investors and analysts:

Participants are requested to dial-in 10 minutes before the scheduled time. A DiamondPass™ link is also available for joining without wait time. The intimation was signed by Company Secretary Ritu Tiwary on May 14, 2026.

About Shilpa Medicare Limited

Shilpa Medicare Limited is an integrated pharmaceutical group with interests in niche Oncology & Non-oncology APIs, Peptides, Polymers, and finished dosage formulations. The company provides end-to-end CDMO services supported by four R&D units and seven manufacturing facilities.

Shilpa Medicare Limited has announced the appointment of Dr. Vellaian Karuppiah as Chief Operating Officer (COO) - Formulations, effective 23 April 2026. The appointment has been duly approved by the Nomination and Remuneration Committee of the company and was disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointment Details

The appointment of Dr. Karuppiah as a Senior Managerial Personnel follows the prescribed regulatory requirements. The disclosure was made in compliance with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated 30th January 2026. The key details of the appointment are outlined below:

Professional Background

Dr. Vellaian Karuppiah, aged 52 years, brings over 33 years of extensive and diverse experience across the pharmaceutical value chain. His expertise spans multiple critical areas including Formulation & Analytical R&D, Regulatory Affairs, Manufacturing Science & Technology (MS&T), Technology Transfer, Engineering & Projects, Quality Systems, EHS/ESG, Supply Chain Management, PPIC, and end-to-end Manufacturing Operations.

Throughout his career, Dr. Karuppiah has held senior leadership and C-suite positions in several globally reputed pharmaceutical organizations. His previous roles include positions at Gland Pharma Limited (Fosun Group), Strides Group, Dr. Reddy's Laboratories, Actavis (now Teva), and Orchid Healthcare (Hospira/Pfizer). Most recently, he served as Chief Operating Officer at Acme Group and Immacule Lifesciences.

Educational Qualifications

Dr. Karuppiah holds a Postgraduate degree and Doctorate in Pharmacy. Additionally, he has acquired Executive Management qualifications from premier Tier-1 institutions in India and abroad, further strengthening his strategic orientation and leadership capabilities.

Strategic Impact

The company expects that Dr. Karuppiah's proven leadership capabilities, strategic orientation, and rich industry experience will significantly strengthen Shilpa Medicare Limited's Formulation business operations. His appointment is anticipated to enhance operational efficiencies, improve manufacturing efficiency, strengthen supply chain resilience, and support long-term sustainable growth for the organization.